Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
09/2005
09/29/2005WO2005090575A1 Glycosylation variants of ricin-like proteins
09/29/2005WO2005090574A1 Vascular endothelial growth inhibiting gene
09/29/2005WO2005090573A2 Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
09/29/2005WO2005090570A1 Therapeutic compositions and methods for treating diseases that involve angiogenesis
09/29/2005WO2005090569A1 Cancer and testis vsm1 and vsm2 nucleic acids, proteins and uses thereof
09/29/2005WO2005090564A1 Gene promoting vascular endothelial cell growth
09/29/2005WO2005090559A1 Methods and compositions involving s-ship promoter regions
09/29/2005WO2005090378A1 Ligands of the molecule fit (agt-121) and their pharmaceutical use
09/29/2005WO2005089822A1 Medicine/gene leaching type stent
09/29/2005WO2005089811A1 Materials for treating vascular leakage in the eye
09/29/2005WO2005089810A1 Method of inducing bone by transferring human osteogenetic factor gene with the use of electroporation method
09/29/2005WO2005089801A1 Method of preventing ultraviolet ray-induced apoptosis
09/29/2005WO2005089800A1 PHARMACEUTICAL COMPOSITION CONTAINING hsHRD3
09/29/2005WO2005089791A1 Pea15 as a tumor suppressor gene
09/29/2005WO2005089712A1 Lyophilization method to improve excipient crystallization
09/29/2005WO2005089443A2 Combinatorial methods and compositions for treatment of melanoma
09/29/2005WO2005089411A2 Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
09/29/2005WO2005089398A2 Method for the delivery of sustained release agents
09/29/2005WO2005089287A2 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
09/29/2005WO2005089252A2 Methods and compositions for the treatment of obesity
09/29/2005WO2005089247A2 Antisense composition and method for treating cancer
09/29/2005WO2005089231A2 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
09/29/2005WO2005089224A2 iRNA AGENTS TARGETING VEGF
09/29/2005WO2005089148A2 Delivery of genes encoding short hairpin rna using receptor-specific nanocontainers
09/29/2005WO2005089123A2 Therapeutic anti-cancer dna
09/29/2005WO2005089112A2 Plasma-enhanced functionalization of carbon-containing substrates
09/29/2005WO2005063801A3 Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof
09/29/2005WO2005061002A3 Composition and methods for modulating cns activity
09/29/2005WO2005056752A3 Methods and compositions for delivering polynucleotides
09/29/2005WO2005056051A3 Hepatitis b vaccines and compositions
09/29/2005WO2005046732A3 Methods and compositions for the inhibition of hiv-1 replication
09/29/2005WO2005039642A9 Dna delivery with gemini cationic surfactants
09/29/2005WO2005038005A9 Shc proteins as therapeutic targets in proliferative diseases
09/29/2005WO2005016964A3 Canine specific growth hormone releasing hormone
09/29/2005WO2005003295A3 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds
09/29/2005WO2004108939A8 Bav packaging regions and e1 transcriptional control regions
09/29/2005WO2004070008A8 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
09/29/2005US20050216959 Using biobolistic electric discharge particle acceleration to transfer gold coated beads into cells; improving heterologous gene transfer and expression
09/29/2005US20050215722 Drug delivery compositions and medical devices containing block copolymer
09/29/2005US20050215509 Method for inhibiting jnk-1 kinase activity by SCCA
09/29/2005US20050215508 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
09/29/2005US20050215507 Therapeutic anti-cancer DNA
09/29/2005US20050215506 Antisense nucleotide sequences for inhibiting the expression of tyrosinase; control melanin biosynthetic pathway; treating pigment disorder of eyes, hair, and skin, and melanoma
09/29/2005US20050215505 Genetically engineered soluble form of CD39L3 or fusion protein of soluble form with heterologous sequence; deletions and replacements; anticoagulant, antiinflammatory, antihypoxic, and antiischemic agents; atherosclerosis, arteriosclerosis, preeclampsia, strokes; cardiovascular disorders
09/29/2005US20050215504 Antisense modulation of sterol regulatory element-binding protein-1 expression
09/29/2005US20050215503 HIF oligonucleotide decoy molecules
09/29/2005US20050215502 Regulation of endogenous gene expression in cells using zinc finger proteins
09/29/2005US20050215501 Methods and products for enhancing epitope spreading
09/29/2005US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens
09/29/2005US20050215499 Lipoproteins as nucleic acid vectors
09/29/2005US20050215498 Method for the protection of endothelial and epithclial cells during chemotherapy
09/29/2005US20050215497 Treating prostate cancer by administering double stranded oligonucleotide having two complementary oligonucleotide sequences forming a hybrid; each sequence has at one 3' or 5' end 1-5 unpaired nucleotides forming single-strand ends extending beyond the hybrid
09/29/2005US20050215474 inducing a specific immune response to DNA vaccines; as an adjuvant, immunostimulants
09/29/2005US20050214945 Htlv-I tax induced killing of p53 null cancer cells
09/29/2005US20050214944 Using single-stranded nucleic acids and homologus recombination to correct defects in tumor suppressor genes; treating and preventing cell proliferative disorders; gene therapy
09/29/2005US20050214923 Recombinant viral vector comprising antitumor agents for use in targeted tissue therapy; gene therapy
09/29/2005US20050214910 Chordin-like molecules and uses thereof
09/29/2005US20050214908 Regulation of human transketolase-like enzyme
09/29/2005US20050214869 Molecular interactions in hematopoietic cells
09/29/2005US20050214856 Nucleotide sequences coding bone morphogenic protein for identifying modulators for treatment of bone diseases
09/29/2005US20050214851 Linearized vector for heterologus gene transfer, control and expression
09/29/2005US20050214844 Nucleotide sequences coding translocation protein for use in identifying modulators for prevention and treatment of cell proliferative ,inflammatory and autoimmune disorders
09/29/2005US20050214837 Antibody specific for mutant presenilin 1 and method of use thereof
09/29/2005US20050214818 Using cells expressing armitage (ARMI) polypetide as models for id entifying modulators of cell proliferative disorders
09/29/2005US20050214781 Ovarian specific nucleic acid (OSNA) for use in diagnosis, prevention and treatment of cell proliferative disorders; immunotherapy; genetic vaccines
09/29/2005US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders
09/29/2005US20050214771 Methods for identifying risk of breast cancer and treatments thereof
09/29/2005US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins
09/29/2005US20050214535 Plasma-enhanced functionalization of carbon-containing substrates
09/29/2005US20050214321 Recombinant icosahedral virus like particle production in pseudomonads
09/29/2005US20050214311 Immunocomplex of an antigen, especially a tumor-associated antigen, bacterial or viral antigen, and Fas ligand as an adjuvant; fusion protein; nucleic acid; treating cancer
09/29/2005US20050214300 Methods for treating cancer using Porimin as a target
09/29/2005US20050214296 Methods of modulating cytokine activity; related reagents
09/29/2005US20050214292 Monitoring and inhibiting midkine gene expression activity; lupus nephritis; kits
09/29/2005US20050214281 G-protein coupled receptor
09/29/2005US20050214268 Methods for treating tumors and cancerous tissues
09/29/2005US20050214267 Compositions and methods for controlling insects related to the octopamine receptor
09/29/2005US20050214266 Pretreating hematopoietic stem cells harvested from blood or bone marrow, tissue materials and/or organs prior to surgical implantation; preventing infections
09/29/2005US20050214265 Tolerance conditioning and multiday delayed transplantation; depleting alpha beta - and gamma delta -TCR+ T cells and/or CD8+ T cells
09/29/2005US20050214264 Engineered to include recombinant lytic factor; evades host immune system; high capacity, target cell specificity; genes and nonnucleic acid materials
09/29/2005US20050214262 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine
09/29/2005US20050214258 Vectors for delivering viral and oncogenic inhibitors
09/29/2005US20050214256 Expression cassette generated from these sequences; generating an immune response in a subject
09/29/2005US20050214252 Chordin-like molecules and uses thereof
09/29/2005CA2560636A1 Glycosylation variants of ricin-like proteins
09/29/2005CA2560269A1 Combinatorial methods and compositions for treatment of melanoma
09/29/2005CA2560261A1 Method for the delivery of sustained release agents
09/29/2005CA2559955A1 Methods and compositions for the specific inhibition of gene expression by double-stranded rna
09/29/2005CA2559936A1 Methods and compositions for using alveolar macrophage phospholipase a2
09/29/2005CA2559840A1 Prostatic acid phosphatase antigens
09/29/2005CA2559720A1 Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase
09/29/2005CA2559665A1 Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
09/29/2005CA2559586A1 Methods and compositions involving s-ship promoter regions
09/29/2005CA2559436A1 Materials for treating vascular leakage in the eye
09/29/2005CA2559211A1 Detection, isolation and uses of renalase (monoamine oxidase c)
09/29/2005CA2559161A1 Irna agents targeting vegf
09/29/2005CA2558371A1 Methods of modulating immune responses by modulating tim-1 and tim-4 function
09/29/2005CA2557836A1 Antisense composition and method for treating cancer
09/29/2005CA2557443A1 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
09/29/2005CA2554018A1 Lyophilization method to improve excipient crystallization
1 ... 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 ... 870